News

Hyqvia consists of Immune Globulin Infusion 10% (Human) (IG 10%) and recombinant human hyaluronidase developed by Halozyme. The immune globulin treatment for PI in adults was approved by

Per the original collaboration agreement signed in December 2006, Enanta will be eligible for certain regulatory approval milestones as well as royalties on net sales allocable to ABT-493

RNS60 is a therapeutic saline containing highly potent charge-stabilized nanostructures (CSNs) that decrease inflammation and cell death. Revalesio demonstrated the ability of RNS60 to reduce the inflammatory responses

The stated goal of Cannabics Pharmaceuticals is to be one of the first and few companies in the world to commercialize indication specific and clinically tested cannabis-based medical

A Compassionate Use IDE allows access to an unapproved product for U.S. patients with serious or life-threatening conditions for whom the treating physician believes the treatment may provide

This license agreement combines Apricus’ expertise in men’s health with Forendo’s established leadership in SERM drug discovery, to advance the development of fispemifene as an investigational treatment for

If approved, it would be the first pediatric combination vaccine in the US designed to help protect against six important diseases including diphtheria, tetanus, pertussis (whooping cough), polio

The US Food and Drug Administration (FDA) has approved Contrave as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with

In 2011, MedImmune licensed the OX40 agonist platform from AgonOx as a result of a partnership between the Providence Cancer Center and AgonOx, a spin-off company from the